- Home
- EWBC vs RPRX Comparison
EWBC vs RPRX Comparison
Compare EWBC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWBC
- RPRX
- Stock Information
- Founded
- EWBC 1998
- RPRX 1996
- Country
- EWBC United States
- RPRX United States
- Employees
- EWBC N/A
- RPRX N/A
- Industry
- EWBC Major Banks
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- EWBC Finance
- RPRX Health Care
- Exchange
- EWBC Nasdaq
- RPRX Nasdaq
- Market Cap
- EWBC 14.6B
- RPRX 15.6B
- IPO Year
- EWBC 1999
- RPRX 2020
- Fundamental
- Price
- EWBC $106.73
- RPRX $35.42
- Analyst Decision
- EWBC Buy
- RPRX Strong Buy
- Analyst Count
- EWBC 13
- RPRX 3
- Target Price
- EWBC $115.92
- RPRX $45.33
- AVG Volume (30 Days)
- EWBC 853.4K
- RPRX 4.0M
- Earning Date
- EWBC 10-21-2025
- RPRX 11-05-2025
- Dividend Yield
- EWBC 2.26%
- RPRX 2.49%
- EPS Growth
- EWBC 9.78
- RPRX 54.86
- EPS
- EWBC 8.56
- RPRX 2.32
- Revenue
- EWBC $2,455,502,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- EWBC $6.09
- RPRX $33.77
- Revenue Next Year
- EWBC $6.68
- RPRX $4.62
- P/E Ratio
- EWBC $12.42
- RPRX $15.19
- Revenue Growth
- EWBC 4.10
- RPRX 3.02
- 52 Week Low
- EWBC $68.27
- RPRX $24.05
- 52 Week High
- EWBC $113.95
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- EWBC 51.96
- RPRX 43.40
- Support Level
- EWBC N/A
- RPRX $34.84
- Resistance Level
- EWBC $110.48
- RPRX $36.94
- Average True Range (ATR)
- EWBC 2.28
- RPRX 0.87
- MACD
- EWBC -3.94
- RPRX -0.09
- Stochastic Oscillator
- EWBC 96.33
- RPRX 41.91
About EWBC East West Bancorp Inc.
East West Bancorp Inc operates in U.S. and Asia. The Bank provides range of personal and commercial banking services to individuals and businesses. In addition to offering traditional deposit products that include personal and business checking and savings accounts, money market, and time deposits, the Bank also offers foreign exchange, treasury management and wealth management services. The Bank has three operating segments, (1) Consumer and Business Banking, (2) Commercial Banking and (3) Treasury and Other. The company generates the majority of its revenue from the Commercial banking segment.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.